Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609234 | 0.92 | SLC2A2 (0.52) | SLC2A2TSPOGABRA2GABRB2LMNA | |
| SCHEMBL611606 | 0.90 | SLC2A2 (0.50) | SLC2A2TSPOGABRA2GABRB2LMNA | |
| SCHEMBL612623 | 0.90 | SLC2A2 (0.59) | SLC2A2MAPTSLC2A1ALDH1A1HPGD | |
| SCHEMBL612687 | 0.90 | GABRA2 (0.51) | SLC2A2TSPOGABRA2GABRB2HPGD | |
| SCHEMBL609135 | 0.88 | HSD17B10 (0.52) | SLC2A2TSPOMEN1KMT2ASLC2A1 | |
| SCHEMBL611052 | 0.85 | SLC2A2 (0.47) | SLC2A2TSPOGABRA2GABRB2LMNA | |
| SCHEMBL611640 | 0.82 | GABRA2 (0.54) | TSPOGABRA2GABRB2LMNAALDH1A1 | |
| SCHEMBL610320 | 0.82 | SLC2A2 (0.55) | SLC2A2GABRA2GABRB2LMNAMAPT | |
| SCHEMBL27761721 | 0.81 | TSPO (0.50) | TSPOGABRA2GABRB2LMNAMAPT | |
| SCHEMBL611641 | 0.81 | GABRA2 (0.53) | TSPOGABRA2GABRB2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | claimed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | claimed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | claimed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | claimed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | claimed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | claimed |
| US-8993562-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-8153789-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-10 | — | — | US | disclosed |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | disclosed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | disclosed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | GABRA5, GABRA1, GABRA2 | SLC2A2 2318/4885TSPO 140/4885GABRA2 3/4885 |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | GABRA5, GABRA1, GABRA2 | SLC2A2 2318/4885TSPO 140/4885GABRA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.